Orlistat: Clinically Proven Weight Management Aid
Orlistat
| Product dosage: 120mg | |||
|---|---|---|---|
| Package (num) | Per cap | Price | Buy |
| 30 | 5.26 $ | 157.95 $ (0%) | 🛒 Add to cart |
| 60 | 4.72 $ | 315.90 $ 283.14 $ (10%) | 🛒 Add to cart |
| 90 | 4.52 $ | 473.85 $ 407.16 $ (14%) | 🛒 Add to cart |
| 120 | 4.44 $
Best per cap | 631.80 $ 532.35 $ (16%) | 🛒 Add to cart |
| Product dosage: 60mg | |||
|---|---|---|---|
| Package (num) | Per cap | Price | Buy |
| 30 | 2.30 $ | 69.03 $ (0%) | 🛒 Add to cart |
| 60 | 1.79 $ | 138.06 $ 107.64 $ (22%) | 🛒 Add to cart |
| 90 | 1.62 $ | 207.09 $ 146.25 $ (29%) | 🛒 Add to cart |
| 120 | 1.53 $ | 276.12 $ 183.69 $ (33%) | 🛒 Add to cart |
| 180 | 1.45 $ | 414.18 $ 260.91 $ (37%) | 🛒 Add to cart |
| 270 | 1.40 $ | 621.27 $ 376.74 $ (39%) | 🛒 Add to cart |
| 360 | 1.36 $
Best per cap | 828.36 $ 491.40 $ (41%) | 🛒 Add to cart |
Synonyms | |||
Orlistat is a lipase inhibitor medication approved for weight management in adults with a body mass index (BMI) of 30 or greater, or 27 or greater with other risk factors such as hypertension, diabetes, or dyslipidemia. It functions by inhibiting gastric and pancreatic lipases in the gut, decreasing the hydrolysis of dietary triglycerides into absorbable free fatty acids and monoglycerides. This results in approximately 30% reduction in fat absorption from the diet. When combined with a reduced-calorie diet, orlistat has been demonstrated to produce significantly greater weight loss than diet alone, supporting long-term weight maintenance and improvement in obesity-related comorbidities.
Features
- Contains orlistat as the active pharmaceutical ingredient
- Available in 60 mg (over-the-counter) and 120 mg (prescription-only) strengths
- White to off-white hard capsules
- Typically supplied in blister packs or HDPE bottles
- Requires storage at room temperature (15–30°C)
- Manufactured under strict pharmaceutical quality standards
Benefits
- Promotes clinically meaningful weight loss when used adjunctively with a hypocaloric diet
- Reduces absorption of dietary fat by approximately one-third, supporting a calorie deficit
- Helps improve obesity-related parameters, including waist circumference and blood pressure
- May contribute to improved glycemic control in patients with type 2 diabetes
- Supports long-term weight maintenance when combined with lifestyle modifications
- Non-systemic mechanism of action with minimal absorption into bloodstream
Common use
Orlistat is indicated for obesity management in adults with an initial BMI ≥30 kg/m², or ≥27 kg/m² in the presence of other risk factors such as hypertension, type 2 diabetes, or hypercholesterolemia. It is used as part of a comprehensive weight management program that includes a nutritionally balanced, reduced-calorie diet containing approximately 30% of calories from fat. Treatment should be discontinued if weight loss is not achieved after 12 weeks.
Dosage and direction
The recommended dosage of orlistat is one 120 mg capsule taken three times daily with each main meal containing fat (during or up to one hour after the meal). Doses may be omitted if a meal is skipped or contains no fat. The capsule should be swallowed whole with water. A daily multivitamin supplement containing fat-soluble vitamins (A, D, E, K) should be taken once daily at least 2 hours before or after orlistat administration, preferably at bedtime.
Precautions
Use with caution in patients with history of hyperoxaluria or calcium oxalate nephrolithiasis. Monitor thyroid function in patients taking levothyroxine concurrently. Periodic monitoring of liver function tests is recommended. Not recommended for use in pediatric patients. Patients should be advised to follow a nutritionally balanced, reduced-calorie diet with no more than 30% of calories from fat to minimize gastrointestinal effects. Pregnancy should be excluded before starting treatment and adequate contraception is recommended during therapy.
Contraindications
Chronic malabsorption syndrome, cholestasis, known hypersensitivity to orlistat or any component of the formulation, breastfeeding, and organ transplant recipients. Concomitant use with cyclosporine is contraindicated. Not recommended for patients with reduced gallbladder function or those who have undergone cholecystectomy.
Possible side effects
Common gastrointestinal effects include oily spotting, flatus with discharge, fecal urgency, fatty/oily stool, oily evacuation, increased defecation, and fecal incontinence. These effects are generally mild to moderate, decrease with continued use, and are associated with high-fat meals. Other reported effects include abdominal pain/discomfort, nausea, infectious diarrhea, rectal pain/discomfort, tooth/gum disorder, headache, upper respiratory infection, back pain, and menstrual irregularity. Rare cases of severe liver injury have been reported.
Drug interaction
May decrease absorption of fat-soluble vitamins (A, D, E, K) and beta-carotene. Concurrent use with cyclosporine is contraindicated. May reduce plasma levels of amiodarone, antiepileptics (e.g., valproate, lamotrigine), and antiretroviral drugs. Separate administration of levothyroxine by at least 4 hours. May potentiate effects of warfarin; monitor INR regularly. Use with caution with other weight-loss agents.
Missed dose
If a dose is missed, it should be skipped and the regular dosing schedule resumed with the next meal. Do not take a double dose to make up for a missed dose.
Overdose
No serious adverse effects have been reported with single doses up to 800 mg. In case of overdose, medical attention should be sought. Treatment should be symptomatic and supportive. A high-fiber diet may help reduce gastrointestinal symptoms.
Storage
Store at room temperature between 15–30°C (59–86°F). Keep container tightly closed. Protect from moisture and light. Keep out of reach of children. Do not use after expiration date printed on packaging.
Disclaimer
This information is for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare professional before starting any new medication or weight management program. Individual results may vary. Proper diagnosis and supervision are essential for safe and effective use.
Reviews
Clinical studies demonstrate that orlistat plus diet produces significantly greater weight loss than placebo plus diet. In one-year trials, 35.5% to 54.8% of patients achieved ≥5% weight loss compared to 21% to 33.4% with placebo. Long-term studies show maintained weight loss and improved cardiovascular risk factors over four years. Patient-reported outcomes indicate satisfaction with weight loss results though gastrointestinal side effects are commonly noted, particularly during the initial treatment period.